Incorrect, RAP also have chronic respiratory management for...

First 177 Last

Share
Profile

Follow
AlCp

26,416 Posts.

1717

10/07/20

17:20

Post #: 45786390
Share

Originally posted by Diamo ↑

As a RSH shareholder I do follow RAP’s progress into their commercialisation strategy as both companies cater for respiratory ailments.

RAP’s App is a diagnostic tool - RSH’s device a monitoring tool. Both have their advantages and do compliment each other!
I hope your approach to launch is the correct one as RSH will benefit greatly with monitoring Asthma after being diagnosed by RAP as such.
So if you don’t mind I keep on following your progression and make the occasional remark about it.

IMHO your positives are the affordable costs involved for your App’s. But both App’s will need the backing of clinicians and ongoing advertising campaigns to see proper financial rewards. Just to rely on income from Telehealth and AppStore won’t do!
At RSH it has taken us many years to gather together a team whose focus is the participation of the medical and pharmaceutical fraternity. Only with this backing will RSH launch its device later in the year.

So I do hope you will have success in the respiratory field, as your success will be ours as well!

Cheers

Expand

Incorrect, RAP also have chronic respiratory management for asthma and COPD in the pipeline already with excellent pre-clinical studies result and clinical trial of screening for COPD is currently occurring and since it's using an algorithm which has received clinical validation for asthma and COPD exacerbation, I can't see why the clinical trial result won't be excellent as well and similar to the pre-clinical studies result.

https://www.resapphealth.com.au/chronic-respiratory-disease/#pubs

Last edited by AlCp: 10/07/20

RAP Price at posting: 14.0¢ Sentiment: Buy Disclosure: Held
9 Upvote

0 Great analysis

Reply